AOH1996 for the Treatment of Refractory Solid Tumors
NCT05227326
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Refractory Malignant Solid Neoplasm
- Osteosarcoma
- Leiomyosarcomas
- Synovial Sarcomas
- Ovarian Cancer
- Non-Small Cell Lung Cancer
- Pancreatic Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- City of Hope Medical Center
- Last updated on ClinicalTrials.gov
- July 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- City of Hope Medical Center · Duarte, CA
- City of Hope at Long Beach Elm · Long Beach, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.